Security Snapshot

Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) Institutional Ownership

CUSIP: 84833T103

13F Institutional Holders and Ownership History from Q4 2017 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

41

Shares (Excl. Options)

23.81MFull value: 23,813,560 · shares · 30 Sep 2026

Price

$1.21

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+3,581,224
Value change
+$2,555,829
Number of holders
41
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
55,705,828
SEC-reported price per share
$1.18
Insider filing price
$1.18
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 84833T103.
  • 41 institutions reported positions in Q3 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 59 to 41 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $47.49MFull value: $47,488,908 · USD · 30 Jun 2026
    to
    $28.86MFull value: $28,858,096 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 41 institutions filings for Q3 2026.

Open SEC evidence

Security key

84833T103

13F reference period

Q3 2026

13F holders

41

13D/G owners

2

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
2
Security
SPRO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GSK plc 16% $6,709,142 9,190,606 GSK PLC 27 Mar 2025
Anson Funds Management LP 2.9% $4,587,932 1,615,469 Anson Funds Management LP 30 Jun 2025
As of 30 Sep 2026, 41 institutional investors reported holding
23.81MFull value: 23,813,560 · shares · 30 Sep 2026
shares of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO). This represents 43% of the company’s total
55.71MFull value: 55,705,828 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
40%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GSK plc 16% 9,190,606 2.2% $11,120,633
Pfizer Inc 4.2% 2,362,348 1.8% $2,905,688
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 2,036,226 0% $2,463,833
MACKENZIE FINANCIAL CORP 3.3% 1,831,254 0% $2,215,817
RENAISSANCE TECHNOLOGIES LLC 2.5% 1,409,783 0% $1,705,837
Affinity Asset Advisors, LLC 2.3% 1,300,000 0.09% $1,573,000
Verdad Advisers, LP 1.4% 805,702 1% $974,900
RAYMOND JAMES FINANCIAL INC 1.4% 755,633 0% $914,316
GEODE CAPITAL MANAGEMENT, LLC 0.9% 499,271 0% $604,426
VANGUARD FIDUCIARY TRUST CO 0.52% 287,648 0% $348,054
TWO SIGMA INVESTMENTS, LP 0.48% 267,195 0% $323,306
STATE STREET CORP 0.45% 251,251 0% $304,014
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.36% 201,937 0% $244,344
MARSHALL WACE, LLP 0.35% 195,416 0% $236,453
Invesco Ltd. 0.3% 165,530 0% $200,291
Employees Retirement System of Texas 0.22% 125,081 0% $151,000
XTX Topco Ltd 0.19% 104,323 0% $126,231
DIMENSIONAL FUND ADVISORS LP 0.16% 91,287 0% $110,411
Empowered Funds, LLC 0.11% 63,741 0% $77,127
StoneX Group Inc. 0.07% 38,241 0% $45,844
PANAGORA ASSET MANAGEMENT INC 0.06% 32,762 0% $39,642
TWO SIGMA SECURITIES, LLC 0.06% 32,684 0% $39,548
Capital Asset Advisory Services LLC 0.06% 32,548 0% $36,779
Three Seasons Wealth, LLC 0.05% 30,000 0% $36,300
OPPENHEIMER & CO INC 0.05% 26,750 0% $32,368

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
36
Headline period
Q3 2026
Rows shown
1-25 of 36
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 23,813,560 $28,858,096 +$2,555,829 $1.21 41
2026 Q2 21,447,770 $47,488,908 +$1,578,960 $2.21 59
2026 Q1 20,643,241 $48,297,782 -$1,117,274 $2.34 50
2025 Q4 21,119,398 $49,213,763 +$1,640,743 $2.33 56
2025 Q3 11,311,502 $21,264,964 -$925,483 $1.88 47
2025 Q2 11,078,704 $32,127,617 -$7,947,299 $2.90 44
2025 Q1 15,108,016 $10,875,927 -$477,165 $0.72 38
2024 Q4 15,679,985 $16,148,583 +$400,519 $1.03 50
2024 Q3 12,343,754 $16,539,251 -$2,018,983 $1.34 46
2024 Q2 13,876,978 $18,039,320 +$23,111 $1.30 47
2024 Q1 13,757,012 $23,665,168 -$10,720 $1.72 54
2023 Q4 13,365,697 $19,647,483 +$254,060 $1.47 46
2023 Q3 14,186,051 $17,161,812 -$230,667 $1.21 53
2023 Q2 14,363,122 $20,824,354 +$224,803 $1.45 56
2023 Q1 14,249,435 $20,599,780 -$6,707 $1.45 46
2022 Q4 14,222,474 $24,601,496 -$11,539,486 $1.73 57
2022 Q3 19,852,133 $39,711,772 +$134,944 $2.00 61
2022 Q2 20,944,051 $15,519,733 -$13,723,970 $0.74 60
2022 Q1 20,241,451 $176,086,818 +$3,320,960 $8.70 96
2021 Q4 19,791,141 $316,661,728 +$1,752,850 $16.01 82
2021 Q3 18,370,536 $338,246,936 +$16,477,961 $18.41 87
2021 Q2 16,107,401 $224,862,846 -$15,083,084 $13.96 82
2021 Q1 18,548,675 $273,055,350 +$11,246,827 $14.72 89
2020 Q4 19,088,635 $370,127,115 +$23,864,503 $19.39 87
2020 Q3 16,774,007 $187,077,092 +$55,385,284 $11.16 77
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .